SB202190 (FHPI)

Catalog No.S1077

SB202190 (FHPI) Chemical Structure

Molecular Weight(MW): 331.34

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 58 Publications

Purity & Quality Control

Choose Selective p38 MAPK Inhibitors

Biological Activity

Description SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM in cell-free assays, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Targets
p38α [1]
(Cell-free assay)
p38β [1]
(Cell-free assay)
50 nM 100 nM
In vitro

SB 202190 significantly inhibits both basal and anti-Fas antibody-induced MAPKAPK 2 activity in a dose-dependent manner. SB202190 by itself is sufficient to induce cell death in Jurkat and HeLa cells through activation of CPP32-like caspases, which can be blocked by expression of bcl-2. SB202190-induced apoptosis is attenuated by p38β but augmented by p38α. [2] SB 202190 strongly inhibits UVB induced COX-2 protein expression in HaCaT cells, and markedly inhibits UVB induced cox-2 mRNA. [3] SB 202190 treatment inhibits the expression of albumin-induced proinflammatory (monocyte chemoattractant protein-1) and transforming growth factor (TGF)-beta1-induced profibrotic (procollagen-Ialpha1) genes over 50% in renal tubular cells (normal rat kidney-52E). [4] SB 202190 treatment induces phosphorylation of JNK in a dose- and time- dependent manner in A549 cells, induces phosphorylation of ATF-2 transcription factor, and increases AP-1 DNA binding. [6] SB 202190 treatment enhances the growth of THP-1 and MV4-11 cells. SB 202190 increases the phosphorylation of c-Raf and ERK, suggesting that Ras-Raf-MEK-mitogen-activated protein kinase (MAPK) pathway activation is involved in the leukemia cell growth induced by SB 202190. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCT-116 NYC5TmFDTnWwY4Tpc44hSXO|YYm= M1fTflI2KM7:TR?= M{nqelMxKG2rbh?= MoDaSG1UV8Li Mn3LZZR1\W63YYTld{B1cGVibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:wIH;mJIhDTC1{IHnuJJJme3CxboPpeoUhfG9iRFG= MmXHNlYzOjN{NUG=
MDA-MB-231 MYfGeY5kfGmxbjDBd5NigQ>? NYW5OXI1OiEQvF2= NIDMfHozPCCq Mn7FcIV{e2WwZYOgR2NNOiCrbnT1Z5Rqd25iYomgWG5H|rF? M2LybVI3OTByOES4
rBMSCs NUnVNJNITnWwY4Tpc44hSXO|YYm= M2fEN|ExKM7:TR?= MoTONk42KGh? NHPC[Gdl\XC{ZYPz[ZMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDFVmsh[W6mIICzPC=> NYK2SJZTOjZyNUOyOlY>
MG63 NITyNGdHfW6ldHnvckBCe3OjeR?= M3rTdFExNzJyL{OwJO69VQ>? MV[yOEBp MX3zbYdvcW[rY3HueIx6KGSnY4LlZZNmeyC2aHWgcIV3\Wxib3[gdIhwe3Cqb4L5cIF1\WRicEO4JIlv\HWlZXSgZpkhS2SFbEKgbY4h[SClb37j[Y51emG2aX;uJE1l\XCnbnTlcpQhdWGwbnXy MlXJNlU6QTh|MUK=
MG63 NXzJSIc6SXCxcITvd4l{KEG|c3H5 MWWxNE8zOC9|MDFOwG0> M3XFfFI1KGh? MUTzbYdvcW[rY3HueIx6KGSnY4LlZZNm\CC2aHWgZZBweHSxc3nzJJJifGVib3[gUWc3OyCrbnT1Z4VlKGK7IFPkR4wz NWP4RY5rOjV7OUizNVI>
HTSMCs NULTZZVqTnWwY4Tpc44hSXO|YYm= NUjrcpM{OC5zL{GvNVAh|ryP NFzsR2cyKGh? NF\MfZlqdmirYnn0[YQhS0:UTT2yMYlv\HWlZXSgTG8uOSCycn;0[YlvKGyndnXsd{BidmRibWLORUBmgHC{ZYPzbY9v NHfpfGszPTl{MUS2OC=>
MIA PaCa-2 NIT4b2NHfW6ldHnvckBCe3OjeR?= MX[yNOKh|ryP MX6yOEBp MY\y[YR2[2WmIHzhZ5RifGViYXPjeY12dGG2aX;uJIlvKGOxbXLpcoF1cW:wIIfpeIgh[m:2aDCyMWRIKGGwZDDEMYFtdG:|ZdMg NXuyToRNOjV6OEi0PFk>
MIA PaCa-2 NXuy[WJjTnWwY4Tpc44hSXO|YYm= MlfaNlDDqM7:TR?= NXXlV5JTOjRiaB?= MV7y[ZN2dHS|IHnuJIEhdW:mZYP0JIlvcGmkaYTpc44hd2ZiSFnGMVHPuSCycn;0[YlvKGGlY4XteYxifGmxbh?= MWiyOVg5QDR6OR?=
BxPC-3 NEPwcXVHfW6ldHnvckBCe3OjeR?= NF2wNIEzOMLizszN NEjXS5MzPCCq M1XDSZJme3WudIOgbY4h[SCvb3Tld5QhcW6qaXLpeIlwdiCxZjDITWYuOc7zIIDyc5RmcW5iYXPjeY12dGG2aX;u NXjuTG1VOjV6OEi0PFk>
AsPC-1 NWDKTZhyTnWwY4Tpc44hSXO|YYm= M2fSSVIxyqEQvF2= NYDvXnBzOjRiaB?= NWP0PW5jemW|dXz0d{BqdiCjIH3v[IV{fCCrbnjpZol1cW:wIH;mJGhKTi1zzsGgdJJwfGWrbjDhZ4N2dXWuYYTpc44> NYH0WWg4OjV6OEi0PFk>
MIA PaCa-2 NFfn[ZpHfW6ldHnvckBCe3OjeR?= M1zr[VIxyqEQvF2= MnLxNlQhcA>? NYe3dnVH\W6qYX7j[ZMh[2ynYY\h[4Uhd2ZiUFHSVEB4cGWwIHPvcYJqdmWmIIfpeIgh\2y3Y3;z[UBidmGub3fz MYOyOVg5QDR6OR?=
MIA PaCa-2 M1nGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHsVXkzOMLizszN M3PxUVIhcA>? NIPEZlZ{\W6|aYTpfoV{KGOnbHygcIlv\XNidH:geJJm[XSvZX70JJdqfGhiMj3ES{BidmRiRD3hcIxwe2V? Mn6xNlU5QDh2OEm=
BxPC-3 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\sNlDDqM7:TR?= MXKyJIg> MmrSd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm MlLRNlU5QDh2OEm=
AsPC-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLMNlDDqM7:TR?= MV6yJIg> NX7BbFRwe2Wwc3n0bZpmeyClZXzsJIxqdmW|IITvJJRz\WG2bXXueEB4cXSqIEKtSGch[W6mIFStZYxtd3On NUfhTY53OjV6OEi0PFk>
HEY MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PN[FIxyqEQvF2= NHnrVWMzKGh? Mljnd4Vve2m2aYrld{Bk\WyuIHzpcoV{KHSxIITy[YF1dWWwdDD3bZRpKDJvRFegZY5lKERvYXzsc5Nm MVGyOVg5QDR6OR?=
OVCAR-3 M3zOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\lNlDDqM7:TR?= M1X4O|IhcA>? M2L2TJNmdnOrdHn6[ZMh[2WubDDsbY5meyC2bzD0doVifG2nboSge4l1cCB{LVTHJIFv\CCGLXHscI9{\Q>? NHOwPWQzPTh6OES4PS=>
SK-OV-3 M1HjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MViyNOKh|ryP NVHHNoFFOiCq MVnz[Y5{cXSrenXzJINmdGxibHnu[ZMhfG9idILlZZRu\W62IIfpeIghOi2GRzDhcoQhTC2jbHzvd4U> MXOyOVg5QDR6OR?=
MH7A  MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjqepVWOjRiaB?= NGjET5Rz\WmwZn;yZ4V{KHSqZTDpcohq[mm2b4L5JIVn\mWldIOgc4YhYEGQ Ml21NlU5PjJ7Nk[=
MH7A  MVPBdI9xfG:|aYOgRZN{[Xl? NWjSOGxiOjVizszN NV7rR5htOjRiaB?= M3rsWJJmfmW{c3XzJINmdGxiY4njcIUh[XK{ZYP0JIlv\HWlZXSgZpkhYEGQIHHu[EBk[XW|ZXSgZZBweHSxc3nzJI9nKGOnbHzzJJZq[SCjY4TpeoF1cW:wIH;mJGpPUw>? MlLXNlU5PjJ7Nk[=
SCC25 NYnZPZdTTnWwY4Tpc44hSXO|YYm= MXmyNEDPxE1? M{nCcVI1KGh? MV;pcoNz\WG|ZYOgZZV1d3CqYXf5JIxmfmWu MoHNNlU5OzR2MEC=
HaCaT  NEPUV3BHfW6ldHnvckBCe3OjeR?= MoLOOUDDvU1? NH3lcXUzPCCq NFvDVppqdmirYnn0d{BKTk5vzsOtbY5lfWOnZDDDR2wzOiCycn;keYN1cW:wIHzleoVtew>? MnH3NlU5OzR|NUO=
HaCaT  MnfzSpVv[3Srb36gRZN{[Xl? MXO1JOK2VQ>? NGnQZ4EzPCCq M2KzNYlvcGmkaYTzJGlHVi4QsT3pcoR2[2WmIFPDUFIzKHC{b3T1Z5Rqd25ibHX2[Yx{ M4D6NVI2QDN2M{Wz
HPAEpiCs  NVzZRVlkTnWwY4Tpc44hSXO|YYm= NEKxe4oyNzNxMUCg{txO MnH6NUBp NVfGR404emWmdXPld{BUOVBvaX7keYNm\CCLQ1HNMVEheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9vKGGwZDDwdo9ud3SncjDhZ5Rqfmm2eR?= NX\IZ2wyOjV5M{S5NFA>
HPAEpiCs Ml[0SpVv[3Srb36gRZN{[Xl? NUTuZVk5OS9|L{GwJO69VQ>? NHSxTJAyKGh? M4WwS4lvcGmkaYTzJHMyWC2|dHnteYxifGWmIFHreEBxcG:|cHjvdplt[XSrb36gJOKh M{LmWFI2PzN2OUCw
HPAEpiCs NIHRN5ZHfW6ldHnvckBCe3OjeR?= MkP4NU8{NzFyIN88US=> Mm[3NUBp NWPST2I1cW6qaXLpeJMhWzGSIITpcYUu\GWyZX7k[Y51dHlic4TpcZVt[XSnZDDjMWp2diCyaH;zdIhwenmuYYTpc44> MYqyOVc{PDlyMB?=
K562 MYLGeY5kfGmxbjDBd5NigQ>? NX7rUZkzOTEEoN88US=> NX3rXG1bOcLiaB?= NGfSUYVFVVOR M1rBe4lvcGmkaYTzJJF2cW6jY4LpcoUucW6mdXPl[EBxOzhiTVHQT{BxcG:|cHjvdplt[XSrb36= MmL3NlU3QDRyNEO=
PANC-1 M4LRNWZ2dmO2aX;uJGF{e2G7 NH7rXooyOCEQvF2= M2HoNVEhcA>? M3G0[YVvcGGwY3XzJJRp\SCjdYTvdIhi\2mlIHXm[oVkfMLi M1naVVI2PjN{MkKy
BxPC-3 NGXNSJhHfW6ldHnvckBCe3OjeR?= MW[xNEDPxE1? NHnQT2YyKGh? NW\hR4lW\W6qYX7j[ZMhfGinIHH1eI9xcGGpaXOg[YZn\WO2wrC= Ml\FNlU3OzJ{MkK=
K562  NV3WenpTTnWwY4Tpc44hSXO|YYm= MYWwMlI2NTFizszN NGn5ZXEzPCCq MX\zeZBxemW|c3XzJJJme3[ncnH0do9tNWmwZIXj[YQhUDKDWDDwbI9{eGixconsZZRqd25? MXeyOVYyQTN7Mh?=
THP-1 NUXtZXIzTnWwY4Tpc44hSXO|YYm= MV61JOK2VQ>? MnXhNkBp NHrNTWJ{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgd4VkemW2aX;uJI9nKEmOLUJOtUBqdmS3Y3XkJIJ6KDJ5T1jDbI9tKHCudYOgSnNNNTIEoB?= M2r6fFI2PTl6Nk[x
WB MXfGeY5kfGmxbjDBd5NigQ>? NV61UXpSOjEkgJpOwG3DqA>? M3u0XFMx6oDLbXnu MXzk[YNz\WG|ZYOgeIhmKEySUz2gc5IhVFSDLXnu[JVk\WRiSVytOkBidmRiVF7GMe6yyqCycn;keYN1cW:w NYW1NFdXOjV3M{C2PFI>
RAW 264.7 M{[xVWZ2dmO2aX;uJGF{e2G7 NWLTSXJ6OTEEoN88US=> MmPUN|DjiImvaX6= M1mydolv\HWlZYOgZ4hiemGldHXybZN1cWNidnHjeY9t[XSrb36gc4YhV0O|wrC= MYCyOVQ3OTN7OR?=
RAW 264.7 NEezRpRHfW6ldHnvckBCe3OjeR?= MXGxNOKh|ryP MVGzNQKBkW2rbh?= M3r3WYF1fGWwdXH0[ZMhfGinIHXm[oVkfHNib3[gU3BIKG:wIH;zeIVw[2yjc4SgdoV1emGldHnvci=> M2LVSlI2PDZzM{m5
HaCaT  NYHmR2tyTnWwY4Tpc44hSXO|YYm= M4HNflQxyqEQvF2= MmHmN{0zPCCq MYXEUXNQ NYjue|h4emWmdXPld{B1cGViYXPjeY12dGG2aX;uJI9nKFqRLUG= MoHpNlU1OzV2OEW=
H9c2 NXLHSnlSTnWwY4Tpc44hSXO|YYm= NGTEOXo2OMLizszNxsA> NXLkXlVWOTJiaB?= MkLzdoVlfWOnczDMSGghemWuZXHz[UBidmRiTV3QJIxwe3N? MoPKNlUzPDV6MUi=
HSCs MXvBdI9xfG:|aYOgRZN{[Xl? M{\4UFI2KM7:TR?= MkLxNlTDqGh? NH76d3h{cWewaX\pZ4FvfGy7IHH0eIVvfWG2ZYOgWGcucW6mdXPl[EBi[3SrdnH0[YQhUFOFczDhdI9xfG:|aYO= NHuzVo4zPDl4MUm1NC=>
THP-1 M{f1d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXNOJg4OiCq NXPGNFJ5TE2VTx?= NX\EU4VPUUN3ME20MlfPxE1? NEXjUVUzPDhzNUC4Oy=>
MDDCs NXvpZXNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT1WpZqPzJiaB?= NXzOeYVsTE2VTx?= M3jMbGlEPTB{LkhOwG0> MYCyOFgyPTB6Nx?=
MDDCs MnPKSpVv[3Srb36gRZN{[Xl? NIrTXIQxNTF3IN88US=> Mo\rOFghcA>? MWXEUXNQ M{izOJN2eHC{ZYPz[ZMhUU[QLd8xJIFv\CCLUD2xNEBxem:mdXP0bY9vyqB? MnTYNlQ5OTVyOEe=
MDDCs NHu3bFhHfW6ldHnvckBCe3OjeR?= NVr6b5lZOC1zNTFOwG0> MXm0PEBp MVvEUXNQ Mly0bY5pcWKrdIOgUWlRNTGjLDDNTXAuOWJiYX7kJHJCVlSHUzDwdo9lfWO2aX;u M1fPPVI1QDF3MEi3
MDDCs NIPJcGZHfW6ldHnvckBCe3OjeR?= NWXTepFHOTBizszN MkDqN{42KGh? NIfETW9FVVOR NUj4fpFX[myxY3vzJGVDV1ZiR2CsJIJ2fCCwb4SgWnNXKEdibXXkbYF1\WRiZX70dpkhcW62bzDoeY1idiCPRFTDdy=> M1flWVI1QDF3MEi3
macrophages MVfGeY5kfGmxbjDBd5NigQ>? MlPlNgKBkc7:TR?= NFnweIY1NjYkgJno MVfjc41xdGW2ZXz5JIlvcGmkaYTzJG1VNUmLST3pcoR2[2WmIHHjeIl3[XSrb36gc4YhVkZvzsrC MmLyNlQ5ODh4M{O=
PDL  NW\jWIJPTnWwY4Tpc44hSXO|YYm= MoniNlDDqM7:TdMg NIP3[4M{OCCvaX6= NW\hb3ppTE2VTx?= NXPkOVZ5e2mpbnnmbYNidnSueTDpcohq[mm2czD0bIUhfGWwc3ns[UBnd3KlZT3t[YRq[XSnZDDCUXAuOiCneIDy[ZN{cW:w MUKyOFU3OTB6MR?=
AGS NXT5cYRRTnWwY4Tpc44hSXO|YYm= NVPTZW4zPSEQvF2= NYXUelNFOzBibXnu M{DDdpN2eHC{ZYPz[ZPDqDFvaX7keYNm\CClYYPwZZNmNThiYX7kJINie3Cjc3WtN{Bi[3SrdnH0bY9v M4SxWlI1PTR5OEe4
H520 NWjqdlFDTnWwY4Tpc44hSXO|YYm= MV6xNOKhyrWP NIDEVnoyKGh? NYn5b|ZwTE2VTx?= M1vjSYRm[3KnYYPld{B1cGVicHXt[ZRz\XinZD3pcoR2[2WmIF3TTFIhdVKQQTDhcoQheHKxdHXpckBt\X[nbIO= MlruNlQ2OzB2N{W=
H1703 NHnLdGZHfW6ldHnvckBCe3OjeR?= MV2xNOKhyrWP NWDPeZVsOSCq Mn7iSG1UVw>? MY\k[YNz\WG|ZYOgeIhmKHCnbXX0doV5\WRvaX7keYNm\CCPU1iyJI1TVkFiYX7kJJBzd3SnaX6gcIV3\Wy| NF\pU2YzPDV|MES3OS=>
H520 MoTSSpVv[3Srb36gRZN{[Xl? MV2xNOKhyrWP NEjP[oEyOiCq NHrOZ5NFVVOR M{DY[IlvcGmkaYTzJJBmdWW2cnX4[YQu\WyrY3n0[YQhVVOKMjDwdo91\WmwIIP0ZYJqdGm2eR?= NGDkVlMzPDV|MES3OS=>
H1703 MoP2SpVv[3Srb36gRZN{[Xl? NYO5N|ZVOTEEoNM1US=> NGrjNYgyOiCq MmDXSG1UVw>? MmHCbY5pcWKrdIOgdIVu\XS{ZYjl[E1mdGmlaYTl[EBOW0h{IIDyc5RmcW5ic4ThZoltcXS7 NUDzb4pxOjR3M{C0O|U>
H520 NYXZdYs4TnWwY4Tpc44hSXO|YYm= MlfUNVDDqML3TR?= M1W0c|YhcA>? NHXNV|JFVVOR MYfzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV? NF\ORnUzPDV|MES3OS=>
H1703 Ml3RSpVv[3Srb36gRZN{[Xl? NGfuOGYyOMLiwsXN NGLYZVI3KGh? M3PFOGROW09? MYPzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgcIV3\Wy|IH;mJJVjcXG3aYTpck1kd26sdXfheIVlKE2VSEKgbY4heGWvZYTy[Zhm\C22cnXheIVlyqClZXzsJIxqdmV? MkL3NlQ2OzB2N{W=
MC3T3-E1 MoHySpVv[3Srb36gRZN{[Xl? MoXnNE4{NzNxM{Cg{txO MoTKNUBp MlvXZZR1\W63YYTld{BVVkZvzsGtbY5lfWOnZDDNUXAuQSCneIDy[ZN{cW:wIHnuJIEh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{wrC= Mnz1NlQ2ODJ4OU[=
MC3T3-E1 M1zWd2Z2dmO2aX;uJGF{e2G7 MVizNEDPxE1? NEHpWYEyKGh? NU[0WGFi[XS2ZX71ZZRmeyCWTl[t{tEue3SrbYXsZZRm\CCyM{igUWFRUyCyaH;zdIhwenmuYYTpc44> NWPSfYE2OjR3MEK2PVY>
HUVECs  NXHHfIlwTnWwY4Tpc44hSXO|YYm= MlK1NVDDqML3TR?= NWrPN3U1OSCq NI[ycoNqdmirYnn0d{BVVkZvzsGtbY5lfWOnZDDDXGNNOSCycn;keYN1cW:w MmLUNlQ1QDd7NkS=
AGS  NGC4UIVHfW6ldHnvckBCe3OjeR?= NFi4SGEyOMLiwsXN MmnwN|DDqG2rbh?= MUDpcohq[mm2czDJUE0y|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>? MnL1NlQ1Pzl4OEG=
MKN-45 M13BXGZ2dmO2aX;uJGF{e2G7 M4fxVVExyqEEtV2= MVWzNOKhdWmw MUnpcohq[mm2czDJUE0y|rJvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QA>? M4DINlI1PDd7Nkix
AGS  MVnGeY5kfGmxbjDBd5NigQ>? M{\yPVExyqEEtV2= M4rGSVMxyqCvaX6= M4THfoF1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v M1XZelI1PDd7Nkix
MKN-45 MlXCSpVv[3Srb36gRZN{[Xl? M{WwZ|ExyqEEtV2= M1nWOlMxyqCvaX6= M3\1RoF1fGWwdXH0[ZMhUUxvMd8yMYlv\HWlZXSgS2Eh[2WubDDtbYdz[XSrb36gZY5lKGmwdnHzbY9v NXj4eIVGOjR2N{m2PFE>
AGS  NGXKcGxHfW6ldHnvckBCe3OjeR?= MVyxNOKhyrWP M4PxPFMxyqCvaX6= NFrx[VF{cWewaX\pZ4FvfGy7IHTlZ5Jm[XOnczDJcE0y|rJvaX7keYNm\CCPTWCyJIFv\CCPTWC5JI1TVkFiZYjwdoV{e2mxbh?= MXeyOFQ4QTZ6MR?=
MKN-45 MU\GeY5kfGmxbjDBd5NigQ>? M2fsSVExyqEEtV2= MnXSN|DDqG2rbh?= MUjzbYdvcW[rY3HueIx6KGSnY4LlZZNmeyCLbD2x{tIucW6mdXPl[EBOVVB{IHHu[EBOVVB7IH3SUmEh\XiycnXzd4lwdg>? NEjKO|UzPDR5OU[4NS=>
DCs NFTIVGNHfW6ldHnvckBCe3OjeR?= MUmyNOKh|ryP M3i0Z|HDqGh? Mlnw[IVkemWjc3XzJGlNNTF{IIDyc4R2[3Srb36= M3XYWVI1PDN2NkO2
HUVEC  NFv4[XFHfW6ldHnvckBCe3OjeR?= M4XmXlIxKM7:bdMg M3fRXlUhcA>? NGKwS2ZFVVOR NGjNZlRz\WS3Y3XzJIN6fG:taX7lJIV5eHKnc4Ppc44hdGW4ZXzzJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXy NHn6PGMzPDF6OUC2Ni=>
A 549 NV;E[JZbTnWwY4Tpc44hSXO|YYm= Mn7SOVAh|ryP M2rwclEhcA>? NX7iPHh2\GWlcnXhd4V{KHSqZTDs[ZZmdCCxZjDJUE05yqB? NGDae|czPDF5OU[4PC=>
H520  NEfFWnVHfW6ldHnvckBCe3OjeR?= Mk\qOU8yOCEQvF2= MoW0NUBp NF64XFRFVVOR NXexOXRs\GWlcnXhd4V{KE2VSEKgdJJwfGWrbjDhd{B4\WyuIHHzJI1TVkFibHX2[Yx{KGmwIHfl[ol1cW6rYj3lfJBwe2WmIHPlcIw> NX6zfW9TOjRzM{i5NFM>
H1703  MXjGeY5kfGmxbjDBd5NigQ>? NHHKN|A2NzFyIN88US=> MlPKNUBp MVnEUXNQ M{XuS4Rm[3KnYYPld{BOW0h{IIDyc5RmcW5iYYOge4VtdCCjczDtVm5CKGyndnXsd{BqdiCpZX\peIlvcWJvZYjwc5Nm\CClZXzs NIDtPXUzPDF|OEmwNy=>
H520  MVTGeY5kfGmxbjDBd5NigQ>? MXKxNOKhyrWP NYjSTpBXOTJiaB?= MV7EUXNQ Mmjr[IVkemWjc3XzJG1UUDJibWLORUBidmRicILveIVqdiC|dHHibYxqfHliaX6g[4VncXSrbnniMZRz\WG2ZXSgUnNEVENiY3XscJM> MYWyOFE{QDlyMx?=
H1703  NG[3[WZHfW6ldHnvckBCe3OjeR?= NVq0XINLOTEEoNM1US=> NF7LVlQyOiCq MnzMSG1UVw>? NVjnS5BO\GWlcnXhd4V{KE2VSEKgcXJPSSCjbnSgdJJwfGWrbjDzeIFjcWyrdImgbY4h\2WoaYTpcoljNXS{ZXH0[YQhVlOFTFOgZ4VtdHN? NWi4SVI6OjRzM{i5NFM>
MCF-7  MnrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWixNOKh|ryP MVeyOOKhcA>? NGXoV3ZqdmirYnn0d{B1cGViQ2KxNFgucW6mdXPl[EBk\WyuIHTlZZRp M3[w[FI1OTJ6OEWz
HPAEpiCs MmixSpVv[3Srb36gRZN{[Xl? NXXjWpE5OC5zL{GvNVAh|ryP MUOxJIg> MYfpcohq[mm2czDUUmYu|rFvaX7keYNm\CClUFzBNuKheHKxdHXpckBidmRibWLORUBmgHC{ZYPzbY9v M2XaPFI1ODZ7MUW4
podocytes MXfGeY5kfGmxbjDBd5NigQ>? MWOxNOKh|ryP NFvB[m8yKGh? MYTpcohq[mm2czDUS2bPujFvaX7keYNm\CCjY4TpeoF1cW:wIH;mJJA{QE2DUFugZY5lKEW{a{GvNuKh NW\SV|VvOjRyM{[yNVI>
MCF-7 M2XHe2Z2dmO2aX;uJGF{e2G7 MmTHNVDDqM7:TR?= M{H4ZlEhcA>? MWjEUXNQ M1jtcJJm\HWlZYOgeIhmKFeDLXnu[JVk\WRicHjvd5Bpd3K7bHH0[YQheDN6IF3BVGs> MnjFNlQxOTlyOUC=
MCF-7 MnPPSpVv[3Srb36gRZN{[Xl? Ml;wNVDDqM7:TR?= MYmyOEBp NHO4fGNFVVOR M3PYR4lv[3KnYYPld{B1cGViV1GtbY5lfWOnZDDhdI9xfG:|aYO= NVL4fpFTOjRyMUmwPVA>
HAPI MXvGeY5kfGmxbjDBd5NigQ>? M1jOUlExNzJyL{SwxsDPxE1? NELuPXgyKGh? MXfpcohq[mm2czDUR2RFNWmwZIXj[YQheDN6L1rOT{BOSVCNIIDoc5NxcG:{eXzheIlwdg>? NUDxbXNNOjN7NkmxNlA>
HAPI MlHNSpVv[3Srb36gRZN{[Xl? M3:1ZVIxyqEQvF5CpC=> M1;GPVEhcA>? M1;RWWROW09? M3nHe4F1fGWwdXH0[ZMhXEOGRD3pcoR2[2WmIHHjeIl3[XSrb36gc4YhcU6RUzDhcoQheHKxZIXjeIlwdg>? NH\3em4zOzl4OUGyNC=>
HepG2 MoGzSpVv[3Srb36gRZN{[Xl? NF3XTHM{PTBibl2= MmPENlQhcA>? MW\pcohq[mm2czD0bIUh\GWpdXXsbY4ucW6mdXPl[EBi[3SrdnH0bY9vKG:oIICzPG1CWEt? MmnsNlM6OzNzOUi=
AGS  Mme4SpVv[3Srb36gRZN{[Xl? M3;kV|ExyqEQvF2= MYWzNEBucW5? NYLDUXJPcW6qaXLpeJMh[2G|cHHz[U0{KGGldHn2ZZRqd25iYX7kJIlvcGmkaYTpc44hd2ZiRWLL NYLhdFNKOjN6NUC5PVQ>
HepG2 Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7LNE02OCEQvF2= NEO4flA1QCCq M2LWdolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy MVWyN|gxPzVyOB?=
BEL7404 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVewMVUxKM7:TR?= MlnMOFghcA>? NWL0ZoNjcW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZI> MlPLNlM5ODd3MEi=
HL7702 NHzVeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfPNE02OCEQvF2= MX60PEBp MX\pcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?= MV6yN|gxPzVyOB?=
HepG2 MVXGeY5kfGmxbjDBd5NigQ>? M4LlOlAuPTBizszN MV2yOEBp NX3NbnoxcW6qaXLpeJMhfGinIIDoc5NxcG:{eXzheIlwdiCxZjDwN|gh\G:5boP0doVidSCycn;0[YlveyCPQWDLRXBMOixiQWTGNkwhVVONMTDhcoQhUFOSMkegbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M2fxelI{QDB5NUC4
BEAS-2B MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS1NVAh|ryP MmXvN|AhdWmw M3vjXZJmfmW{c3XzJJRp\SCmZXPy[YF{\SCxZjDj[YxtKH[rYXLpcIl1gSCrbnT1Z4VlKGK7IFjDTS=> NXX3eXp[OjN5OESwN|Q>
BEAS-2B NUDGUJc4S3m2b4TvfIl1gSCDc4PhfS=> NITBbHAyOCEQvF2= MV6zNEBucW5? M2PRT4lvcGmkaYTl[EB1cGViaX7jdoVie2ViaX6gUGRJKGGwZDDJUE05KGW6cILld5Nqd25? M4PNSFI{Pzh2MEO0
BEAS-2B NWrQSoVmTnWwY4Tpc44hSXO|YYm= MmmzNVAh|ryP NHnSU|g{OCCvaX6= MUTk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iClYYPwZZNmNTNuIFLh[EBidmRiZnHz MVGyN|c5PDB|NB?=
H9c2  MWTGeY5kfGmxbjDBd5NigQ>? MYWwMlAyNzBwMT:xJO69VQ>? MWexJIg> NHX5NJpifHSnboXheIV{KFSQRj5OtU1qdmS3Y3XkJG1OWC17IHX4dJJme3Orb36sJI1TVkFibHX2[Yx{NCCjbnSgdJJwdW:2ZYKgZYN1cX[rdIm= NWeyO|FGOjN5N{SyOVI>
H9c2  M2XPSWZ2dmO2aX;uJGF{e2G7 Mn7WNUDPxE1? MX6xJIg> MW\y[YR2[2W|IGTOSk3PuSCmaYLlZ5RtgSC|dHnteYxifGWmIICzPEBOSVCNIIDoc5NxcG:{eXzheIlwdg>? NWexW2psOjN5N{SyOVI>
U937 MULGeY5kfGmxbjDBd5NigQ>? NUnhZ41nOTEEoN88UeKh NUPUN5NVOSCq NUnRZWRi[WK{b3fheIV{KHSqZTDjZYZn\WmwZTDl[oZm[3Rib36gUWtRNTFiYX7kJHBROkGlzsGgcXJPSSC2cnHud4NzcXC2aX;uZYwhdGW4ZXzz M2TkdlI{PzB5M{i3
U937 MmrPSpVv[3Srb36gRZN{[Xl? NH7uSpUyOMLizszNxsA> Mk\WNUBp MkfiZYJzd2ejdHXzJINi\m[naX7lMYlv\HWlZXSgUWtRNTFiZH;3ck1z\We3bHH0bY9vKGGwZDDQVFJC[87zIIXwMZJm\3WuYYTpc44> MlrGNlM4ODd|OEe=
U937 MmS4SpVv[3Srb36gRZN{[Xl? NGjjdW0yOMLizszNxsA> NF7GfXgyKGh? MYLzeZBxemW|c3XzJIMuUnWwIHHu[EBEWkWEIIDoc5NxcG:{eXzheIlwdiCrbjDjZYZn\WmwZT30doVifGWmIHPlcIx{yqB? NFXx[|gzOzdyN{O4Oy=>
A549 NWDoVpVmTnWwY4Tpc44hSXO|YYm= MV6wMlMwOy9|MDFOwG0> MYqxJIg> MVvzbYdvcW[rY3HueIx6KGG2dHXueYF1\XNiQWTQ{tNUNW2nZHnheIVlKEORWD2yJJBzd3SnaX6gZY5lKG2UTlGg[ZhxemW|c3nvckBidmRicILvcY91\XJiYXP0bZZqfHoEoB?= NX7zTZlTOjN4OEC2O|Q>
A549 NUDO[mxCTnWwY4Tpc44hSXO|YYm= NYXQfFZUOTEEoN88UeKh NV33eWRKOC1|MDDtbY4> MYHpcohq[mm2czDBWHDPu1NiaX7keYNm\CCyNEKvdFQ1KE2DUFugZY5lKHB|ODDNRXBMKHCqb4PwbI9zgWyjdHnvci=> MmLuNlM3QDB4N{S=
A549 Ml;TSpVv[3Srb36gRZN{[Xl? MlHVNVDDqM7:TdMg MX2xJIg> NGezWmxqdmirYnn0d{BCXFEQs2OgbY5lfWOnZDDOSk3PwkJicE[1JJN2[nWwaYSgdIhwe3Cqb4L5cIF1cW:wIHHu[EBPTi4QulKgdJJwdW:2ZYKgZYN1cX[rdIm= M3zGUlI{PjhyNke0
A549 MYLGeY5kfGmxbjDBd5NigQ>? NWnNbWt7OTEEoN88UeKh NUOzU4U5OSCq NYK2cW9EemWmdXPld{BCXFEQs2Otd5RqdXWuYYTl[EBkWEyDMjDwbI9{eGixconsZZRqd28EoB?= M{PxfFI{PjhyNke0
A549 NUXJWI5ZTnWwY4Tpc44hSXO|YYm= NELET4EyOMLizszNxsA> MoXpNUBp NWfKVWl2emWmdXPld{BCXFEQs2Ot[Y5p[W6lZXSg[Y57gW2jdHnjJIFkfGm4aYT5JI9nKGOSTFGyxsA> NEe1Um0zOzZ6ME[3OC=>
PC12 M1fLVWZ2dmO2aX;uJGF{e2G7 M4DIXVExNzJyL{SwJO69VQ>? M4jkO|HDqGh? NYfPZlJicW6qaXLpeJMhUk6NIHHu[EBxOzh? NGjD[GIzOzV6NEO1Oy=>
HK-2 NUHvUJNLSXCxcITvd4l{KEG|c3H5 MnGyNlDDqM7:TR?= NGfzfYIzPCCq Ml:5bY5pcWKrdIOgSXJMKGGwZDDwN|hOSVCN M2LRWlI{PTR|MUWx
H9c2 NFHu[nhHfW6ldHnvckBCe3OjeR?= M4fRd|HDqM7:TR?= MoTmNUBp M{XIVJJm\HWlZYOgWG5HNc7zLXnu[JVk\WRiTV3QMVkhdVKQQTDs[ZZmdHNiYX7kJJBzd22xdHXyJIFkfGm4aYT5 MnTQNlM{PTN4OUm=
H9c2 M3vLc2Z2dmO2aX;uJGF{e2G7 MW[xxsDPxE1? NWX1RpR3OSCq NYruWXZCemWmdXPld{BVVkZvzsGt[Y5p[W6lZXSgRXAuOSCycn;tc5RmeiCjY4Tpeol1gQ>? M1;zR|I{OzV|Nkm5
H1650  NV7pVYV5TnWwY4Tpc44hSXO|YYm= NH7yU4gyOMLizszNxsA> M1fqeVEhcA>? M1XCWWROW09? MU\k[YNz\WG|ZYOgZo91cCCycn;0[YlvKGGwZDDtVm5CKGyndnXsd{Bw\iCHUlPDNUBqdiCyYXPsbZRigGWuLXX4dI9{\WUEoHPlcIx{ MVOyN|IzQDZ7Nh?=
H1703 NED4dHlHfW6ldHnvckBCe3OjeR?= NVnKcVREOTEEoN88UeKh NGnv[GoyKGh? MkGySG1UVw>? NIL1cY9l\WO{ZXHz[ZMh[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVteyCxZjDFVmNEOSCrbjDwZYNtcXSjeHXsMYV5eG:|ZXVCpINmdGy| MmGxNlMzOjh4OU[=
H1650  NHzJV|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLOUmUyOMLizszNxsA> MW[xJIg> NFrFOJhFVVOR NFjxWoFmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[3m2b4TvfIlkcXS7 MWmyN|IzQDZ7Nh?=
H1703 M1XJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7Yc20yOMLizszNxsA> M{D0ZlEhcA>? MUjEUXNQ MXzlcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 NF:5NnYzOzJ{OE[5Oi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
mTOR / p-S6K / S6K / p-S6 / p-AKT / p-MK2; 

PubMed: 26844273     


CRC cells were treated with 10 μM SB202190 for 2 h and analyzed for mTOR signaling and on-target inhibition of p38 by immunoblot. 

pJNK1 / pJNK2 / JNK1 / JNK2 ; 

PubMed: 18222647     


A549 cells were treated with DMSO control or with 10 µM of SB202190 for 0.5, 1, 2, 3, 4, or 6 hours, and pJNK and unphosphorylated JNK were detected as described. 

26844273 18222647
Immunofluorescence
p-p38 / MMP9; 

PubMed: 24479681     


Immunocytochemical staining and confocal microscopy confirmed that IL-1β increased activation of p38 (red), and MMP2 and MMP9 (green) expression in MKN-45 GA cells; these effects were blocked by p38 siRNA or the p38 inhibitor SB202190.

24479681
Growth inhibition assay
Cell viability ; 

PubMed: 26844273     


Top panel: CRC cells were treated with various concentrations of SB202190 for 48 h. Lower panel: CRC cells were treated with SB202190 at 10 μM for different times. Cell growth was measured by SRB assay (means ± s.d. in triplet, n = 3 in triplet).

26844273
In vivo Inhibiting p38 by administration of SB 202190 inhibits PV IgG-induced blister formation in the passive transfer mouse model. [5] In the endotoxin model of sepsis, SB 202190 treatment produces a statistically significant survival benefit compared with control. [8]

Protocol

Kinase Assay:

[1]

- Collapse

In vitro kinase assays:

The p38α and p38β are assayed in 25 mM Tris-HCl, pH 7.5, containing 0.1 mM EGTA, with myelin basic protein (0.33 mg/mL) as substrate. Assays are performed either manually for 10 minutes at 30 °C in 50 μL incubations using [γ-33P]ATP, or with a Biomek 2000 Laboratory Automation Workstation in a 96-well format for 40 minutes at ambient temperature in 25 μL incubations using [γ-33P]ATP. The concentrations of ATP and magnesium acetate are 0.1 mM and 10 mM respectively. All assays are initiated with MgATP. Manual assays are terminated by spotting aliquots of incubation on to phosphocellulose paper, followed by immersion in 50 mM phosphoric acid. Robotic assays are terminated by the addition of 5 μL of 0.5 M phosphoric acid before spotting aliquots on to P30 filter mats. All papers are then washed four times in 50 mM phosphoric acid to remove ATP, once in acetone (manual incubations) or methanol (robotic incubations), and then dried and counted for radioactivity.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, and HeLa
  • Concentrations: Dissolved in DMSO, final concentrations ~50 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are serum-starved and then treated with different concentration of SB 202190 for 24 hours. Cell viability is assayed by either trypan blue exclusion or propidium iodide exclusion followed by flow cytometry analysis. The apoptotic nuclei are visualized by H33258 staining.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: C57BL/6J mice injected i.d. with a sterile solution of either control IgG or PV IgG
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 12.5 μg
  • Administration: Administered via i.d.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (199.19 mM)
Ethanol 12 mg/mL (36.21 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% DMSO+30% polyethylene glycol+1% Tween 80
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 331.34
Formula

C20H14N3OF

CAS No. 152121-30-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p38 MAPK Signaling Pathway Map

p38 MAPK Inhibitors with Unique Features

Related p38 MAPK Products

Tags: buy SB202190 (FHPI) | SB202190 (FHPI) supplier | purchase SB202190 (FHPI) | SB202190 (FHPI) cost | SB202190 (FHPI) manufacturer | order SB202190 (FHPI) | SB202190 (FHPI) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID